Dr. Jonathon Parker is a distinguished leader in pharmaceutical regulatory affairs, renowned for over two decades of expertise in CNS therapeutics and drug development. Currently serving as Vice President at Ultragenyx, he leads global regulatory strategies, pioneering innovation in neurology.
With previous roles at Cerevel Therapeutics, Takeda Pharmaceuticals, and Pfizer, Dr. Parker's strategic leadership shaped regulatory landscapes for prominent drugs like Lyrica and Chantix. His academic prowess includes a Ph.D. in Pharmaceutical Sciences, M.S. in Regulatory Affairs, and executive education at MIT and the University of Michigan.
Dr. Parker's impactful career embodies a fusion of academic excellence and industry leadership, continually shaping the future of neuroscience therapeutics and regulatory policy.
Jonathon Parker
Vice President of Neurology, Ultragenyx